Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer

Breast cancer is the second leading cause of death for women worldwide. The heterogeneity of this disease presents a big challenge in its therapeutic management. However, recent advances in molecular biology and immunology enable to develop highly targeted therapies for many forms of breast cancer....

Full description

Saved in:
Bibliographic Details
Published inMolecular cancer Vol. 22; no. 1; pp. 105 - 40
Main Authors Ye, Feng, Dewanjee, Saikat, Li, Yuehua, Jha, Niraj Kumar, Chen, Zhe-Sheng, Kumar, Ankush, Vishakha, Behl, Tapan, Jha, Saurabh Kumar, Tang, Hailin
Format Journal Article
LanguageEnglish
Published England BioMed Central Ltd 06.07.2023
BioMed Central
BMC
Subjects
Angiogenesis
Breast cancer
Cancer
Cancer therapies
Cell cycle
Chemotherapy
Clinical aspects
Clinical trials
Combined Modality Therapy
Cyclin-dependent kinases
Development and progression
Disease management
DNA repair
Drug approval
Drug development
Drug therapy
Enzymes
Epidermal growth factor
Estrogens
Fatalities
FDA approval
Female
Fibroblasts
Growth factors
Health aspects
Humans
Immune checkpoint inhibitors
Immunosuppressive agents
Immunotherapy
Immunotherapy - methods
Ipilimumab
Kinases
Medical prognosis
Metastasis
Molecular biology
Molecular Targeted Therapy - methods
Monosaccharides
Patients
Phosphorylation
Proteins
Radiation therapy
Review
Sugars
Targeted therapies
Therapeutic targets
Triple Negative Breast Neoplasms - drug therapy
Triple Negative Breast Neoplasms - pathology
Vaccination
Targeted therapies
Clinical trials
Breast cancer
Immune-checkpoint Inhibitors
Immunotherapy
Online AccessGet full text

Cover

Abstract Breast cancer is the second leading cause of death for women worldwide. The heterogeneity of this disease presents a big challenge in its therapeutic management. However, recent advances in molecular biology and immunology enable to develop highly targeted therapies for many forms of breast cancer. The primary objective of targeted therapy is to inhibit a specific target/molecule that supports tumor progression. Ak strain transforming, cyclin-dependent kinases, poly (ADP-ribose) polymerase, and different growth factors have emerged as potential therapeutic targets for specific breast cancer subtypes. Many targeted drugs are currently undergoing clinical trials, and some have already received the FDA approval as monotherapy or in combination with other drugs for the treatment of different forms of breast cancer. However, the targeted drugs have yet to achieve therapeutic promise against triple-negative breast cancer (TNBC). In this aspect, immune therapy has come up as a promising therapeutic approach specifically for TNBC patients. Different immunotherapeutic modalities including immune-checkpoint blockade, vaccination, and adoptive cell transfer have been extensively studied in the clinical setting of breast cancer, especially in TNBC patients. The FDA has already approved some immune-checkpoint blockers in combination with chemotherapeutic drugs to treat TNBC and several trials are ongoing. This review provides an overview of clinical developments and recent advancements in targeted therapies and immunotherapies for breast cancer treatment. The successes, challenges, and prospects were critically discussed to portray their profound prospects.
AbstractList Breast cancer is the second leading cause of death for women worldwide. The heterogeneity of this disease presents a big challenge in its therapeutic management. However, recent advances in molecular biology and immunology enable to develop highly targeted therapies for many forms of breast cancer. The primary objective of targeted therapy is to inhibit a specific target/molecule that supports tumor progression. Ak strain transforming, cyclin-dependent kinases, poly (ADP-ribose) polymerase, and different growth factors have emerged as potential therapeutic targets for specific breast cancer subtypes. Many targeted drugs are currently undergoing clinical trials, and some have already received the FDA approval as monotherapy or in combination with other drugs for the treatment of different forms of breast cancer. However, the targeted drugs have yet to achieve therapeutic promise against triple-negative breast cancer (TNBC). In this aspect, immune therapy has come up as a promising therapeutic approach specifically for TNBC patients. Different immunotherapeutic modalities including immune-checkpoint blockade, vaccination, and adoptive cell transfer have been extensively studied in the clinical setting of breast cancer, especially in TNBC patients. The FDA has already approved some immune-checkpoint blockers in combination with chemotherapeutic drugs to treat TNBC and several trials are ongoing. This review provides an overview of clinical developments and recent advancements in targeted therapies and immunotherapies for breast cancer treatment. The successes, challenges, and prospects were critically discussed to portray their profound prospects.
Breast cancer is the second leading cause of death for women worldwide. The heterogeneity of this disease presents a big challenge in its therapeutic management. However, recent advances in molecular biology and immunology enable to develop highly targeted therapies for many forms of breast cancer. The primary objective of targeted therapy is to inhibit a specific target/molecule that supports tumor progression. Ak strain transforming, cyclin-dependent kinases, poly (ADP-ribose) polymerase, and different growth factors have emerged as potential therapeutic targets for specific breast cancer subtypes. Many targeted drugs are currently undergoing clinical trials, and some have already received the FDA approval as monotherapy or in combination with other drugs for the treatment of different forms of breast cancer. However, the targeted drugs have yet to achieve therapeutic promise against triple-negative breast cancer (TNBC). In this aspect, immune therapy has come up as a promising therapeutic approach specifically for TNBC patients. Different immunotherapeutic modalities including immune-checkpoint blockade, vaccination, and adoptive cell transfer have been extensively studied in the clinical setting of breast cancer, especially in TNBC patients. The FDA has already approved some immune-checkpoint blockers in combination with chemotherapeutic drugs to treat TNBC and several trials are ongoing. This review provides an overview of clinical developments and recent advancements in targeted therapies and immunotherapies for breast cancer treatment. The successes, challenges, and prospects were critically discussed to portray their profound prospects. Keywords: Breast cancer, Clinical trials, Immune-checkpoint Inhibitors, Immunotherapy, Targeted therapies
Breast cancer is the second leading cause of death for women worldwide. The heterogeneity of this disease presents a big challenge in its therapeutic management. However, recent advances in molecular biology and immunology enable to develop highly targeted therapies for many forms of breast cancer. The primary objective of targeted therapy is to inhibit a specific target/molecule that supports tumor progression. Ak strain transforming, cyclin-dependent kinases, poly (ADP-ribose) polymerase, and different growth factors have emerged as potential therapeutic targets for specific breast cancer subtypes. Many targeted drugs are currently undergoing clinical trials, and some have already received the FDA approval as monotherapy or in combination with other drugs for the treatment of different forms of breast cancer. However, the targeted drugs have yet to achieve therapeutic promise against triple-negative breast cancer (TNBC). In this aspect, immune therapy has come up as a promising therapeutic approach specifically for TNBC patients. Different immunotherapeutic modalities including immune-checkpoint blockade, vaccination, and adoptive cell transfer have been extensively studied in the clinical setting of breast cancer, especially in TNBC patients. The FDA has already approved some immune-checkpoint blockers in combination with chemotherapeutic drugs to treat TNBC and several trials are ongoing. This review provides an overview of clinical developments and recent advancements in targeted therapies and immunotherapies for breast cancer treatment. The successes, challenges, and prospects were critically discussed to portray their profound prospects.Breast cancer is the second leading cause of death for women worldwide. The heterogeneity of this disease presents a big challenge in its therapeutic management. However, recent advances in molecular biology and immunology enable to develop highly targeted therapies for many forms of breast cancer. The primary objective of targeted therapy is to inhibit a specific target/molecule that supports tumor progression. Ak strain transforming, cyclin-dependent kinases, poly (ADP-ribose) polymerase, and different growth factors have emerged as potential therapeutic targets for specific breast cancer subtypes. Many targeted drugs are currently undergoing clinical trials, and some have already received the FDA approval as monotherapy or in combination with other drugs for the treatment of different forms of breast cancer. However, the targeted drugs have yet to achieve therapeutic promise against triple-negative breast cancer (TNBC). In this aspect, immune therapy has come up as a promising therapeutic approach specifically for TNBC patients. Different immunotherapeutic modalities including immune-checkpoint blockade, vaccination, and adoptive cell transfer have been extensively studied in the clinical setting of breast cancer, especially in TNBC patients. The FDA has already approved some immune-checkpoint blockers in combination with chemotherapeutic drugs to treat TNBC and several trials are ongoing. This review provides an overview of clinical developments and recent advancements in targeted therapies and immunotherapies for breast cancer treatment. The successes, challenges, and prospects were critically discussed to portray their profound prospects.
Abstract Breast cancer is the second leading cause of death for women worldwide. The heterogeneity of this disease presents a big challenge in its therapeutic management. However, recent advances in molecular biology and immunology enable to develop highly targeted therapies for many forms of breast cancer. The primary objective of targeted therapy is to inhibit a specific target/molecule that supports tumor progression. Ak strain transforming, cyclin-dependent kinases, poly (ADP-ribose) polymerase, and different growth factors have emerged as potential therapeutic targets for specific breast cancer subtypes. Many targeted drugs are currently undergoing clinical trials, and some have already received the FDA approval as monotherapy or in combination with other drugs for the treatment of different forms of breast cancer. However, the targeted drugs have yet to achieve therapeutic promise against triple-negative breast cancer (TNBC). In this aspect, immune therapy has come up as a promising therapeutic approach specifically for TNBC patients. Different immunotherapeutic modalities including immune-checkpoint blockade, vaccination, and adoptive cell transfer have been extensively studied in the clinical setting of breast cancer, especially in TNBC patients. The FDA has already approved some immune-checkpoint blockers in combination with chemotherapeutic drugs to treat TNBC and several trials are ongoing. This review provides an overview of clinical developments and recent advancements in targeted therapies and immunotherapies for breast cancer treatment. The successes, challenges, and prospects were critically discussed to portray their profound prospects.
ArticleNumber 105
Audience Academic
Author Tang, Hailin
Kumar, Ankush
Behl, Tapan
Chen, Zhe-Sheng
Li, Yuehua
Dewanjee, Saikat
Jha, Saurabh Kumar
Jha, Niraj Kumar
Vishakha
Ye, Feng
Author_xml – sequence: 1
  givenname: Feng
  surname: Ye
  fullname: Ye, Feng
– sequence: 2
  givenname: Saikat
  surname: Dewanjee
  fullname: Dewanjee, Saikat
– sequence: 3
  givenname: Yuehua
  surname: Li
  fullname: Li, Yuehua
– sequence: 4
  givenname: Niraj Kumar
  surname: Jha
  fullname: Jha, Niraj Kumar
– sequence: 5
  givenname: Zhe-Sheng
  surname: Chen
  fullname: Chen, Zhe-Sheng
– sequence: 6
  givenname: Ankush
  surname: Kumar
  fullname: Kumar, Ankush
– sequence: 7
  surname: Vishakha
  fullname: Vishakha
– sequence: 8
  givenname: Tapan
  surname: Behl
  fullname: Behl, Tapan
– sequence: 9
  givenname: Saurabh Kumar
  surname: Jha
  fullname: Jha, Saurabh Kumar
– sequence: 10
  givenname: Hailin
  surname: Tang
  fullname: Tang, Hailin
BackLink https://www.ncbi.nlm.nih.gov/pubmed/37415164$$D View this record in MEDLINE/PubMed
BookMark eNp9kktr3DAUhU1JaR7tH-iiGLrpxqmelrQqQ-gjEOimpUtxLckTDbY0lezA_PvKM0maCaUIIXH1nSPu5ZxXJyEGV1VvMbrEWLYfMyaK0QaRsrFEvNm9qM4wE23DuJInT-6n1XnOG4SwkIK9qk6pYJjjlp1Vv1b2DoJxowtTrn2ozeCDNzDUkLfOlFrs6wnS2k3O1tOtS7Dd1RBs7cdxDvGhUpRdcpCn2ix26XX1sochuzf350X188vnH1ffmpvvX6-vVjeN4S2bGssM75VjxBoLUjlhFZWUoU4Jgo2yHJgARBTuEFBDJVG9Yr1skXDAJUh6UV0ffG2Ejd4mP0La6Qhe7wsxrTWkyZvBaUz7nnNMDHKWCcs6aWQHDFHuKFdcFK9PB6_t3I3OmjKSBMOR6fFL8Ld6He80RpQwzNri8OHeIcXfs8uTHn02bhgguDhnTSTlRBDJaEHfP0M3cU6hzGqhpJCtEO1fag2lAx_6WD42i6leCd4STNCeuvwHVZZ1ozclNL0v9SPBu6edPrb4kIsCkANgUsw5uf4RwUgv4dOH8OkSPr0Pn94VkXwmMn6CycdlWn74n_QPf07dIQ
CitedBy_id crossref_primary_10_1007_s10528_025_11059_6
crossref_primary_10_1016_j_biomaterials_2024_123020
crossref_primary_10_3390_biomedicines12040895
crossref_primary_10_1016_j_soi_2024_100088
crossref_primary_10_1007_s12672_024_01705_7
crossref_primary_10_32604_cmc_2024_052531
crossref_primary_10_3389_fonc_2024_1381251
crossref_primary_10_1007_s11307_025_01981_x
crossref_primary_10_1021_acs_jmedchem_4c00511
crossref_primary_10_20517_2394_4722_2023_93
crossref_primary_10_1016_j_mtbio_2025_101634
crossref_primary_10_3390_cancers15194821
crossref_primary_10_3390_ph18010118
crossref_primary_10_1186_s12943_024_02150_4
crossref_primary_10_1007_s10528_023_10615_2
crossref_primary_10_1038_s41419_024_07205_4
crossref_primary_10_1016_j_ijbiomac_2024_135072
crossref_primary_10_1016_j_gene_2024_149135
crossref_primary_10_2174_0113816128322894241004051814
crossref_primary_10_1016_j_apsb_2024_08_028
crossref_primary_10_1039_D3RA06189B
crossref_primary_10_1016_j_aca_2024_342762
crossref_primary_10_3390_genes15081093
crossref_primary_10_1007_s00210_024_03208_2
crossref_primary_10_1016_j_ejphar_2024_176877
crossref_primary_10_1002_adbi_202400431
crossref_primary_10_1186_s13046_025_03282_1
crossref_primary_10_1515_jisys_2024_0172
crossref_primary_10_1080_1061186X_2024_2324935
crossref_primary_10_1186_s12885_024_12149_1
crossref_primary_10_3389_fendo_2023_1266679
crossref_primary_10_3389_fimmu_2024_1464092
crossref_primary_10_1080_14712598_2024_2370395
crossref_primary_10_1002_ame2_12382
crossref_primary_10_3389_fonc_2024_1390992
crossref_primary_10_2147_BCTT_S497975
crossref_primary_10_1186_s12885_024_12952_w
crossref_primary_10_3389_fimmu_2024_1460607
crossref_primary_10_1177_00368504251325385
crossref_primary_10_3389_fimmu_2024_1424259
crossref_primary_10_1007_s11051_024_06166_1
crossref_primary_10_1038_s41420_024_02226_6
crossref_primary_10_1002_advs_202309988
crossref_primary_10_1016_j_heliyon_2024_e36616
crossref_primary_10_1016_j_breast_2024_103830
crossref_primary_10_1186_s12905_024_03507_z
crossref_primary_10_3892_ijo_2023_5578
crossref_primary_10_3389_fimmu_2024_1452303
crossref_primary_10_3390_cancers16162862
crossref_primary_10_3390_cancers16213671
crossref_primary_10_1016_j_heliyon_2024_e34000
crossref_primary_10_1080_08830185_2024_2432499
crossref_primary_10_1515_oncologie_2023_0539
crossref_primary_10_3389_fimmu_2023_1258344
crossref_primary_10_1002_bit_28860
crossref_primary_10_1007_s11468_024_02470_7
crossref_primary_10_1093_bib_bbae721
crossref_primary_10_1021_acsanm_4c06172
crossref_primary_10_3389_fimmu_2024_1399754
crossref_primary_10_1080_14656566_2023_2293167
crossref_primary_10_1021_acsami_4c09833
crossref_primary_10_1002_adbi_202400140
crossref_primary_10_1039_D4BM00159A
crossref_primary_10_3389_fonc_2024_1415820
crossref_primary_10_1080_17435889_2024_2403962
crossref_primary_10_1002_cbf_3992
crossref_primary_10_1016_j_phrs_2024_107205
crossref_primary_10_1186_s12951_024_02694_z
crossref_primary_10_1039_D3NR04305C
crossref_primary_10_4251_wjgo_v16_i5_1908
crossref_primary_10_31083_j_fbl2902073
crossref_primary_10_1016_j_drudis_2024_104045
crossref_primary_10_1111_liv_70048
crossref_primary_10_1007_s11033_023_08809_3
crossref_primary_10_3389_fmolb_2024_1394585
crossref_primary_10_34133_bmr_0149
crossref_primary_10_1111_jcmm_18549
crossref_primary_10_1016_j_clbc_2024_02_022
crossref_primary_10_3389_fphar_2024_1382120
crossref_primary_10_1007_s00604_024_06362_9
crossref_primary_10_1016_j_heliyon_2024_e38732
crossref_primary_10_17116_profmed20252801163
crossref_primary_10_1080_21645515_2024_2335728
crossref_primary_10_1097_CJI_0000000000000523
crossref_primary_10_2174_0113895575270904231129062137
crossref_primary_10_1200_OP_24_00871
crossref_primary_10_1186_s13045_025_01660_y
crossref_primary_10_1080_1061186X_2023_2265585
crossref_primary_10_1371_journal_pone_0308411
crossref_primary_10_1016_j_intimp_2024_113750
crossref_primary_10_1186_s11671_024_03985_y
crossref_primary_10_1080_1750743X_2025_2479426
crossref_primary_10_1007_s11864_024_01200_9
crossref_primary_10_1080_21645515_2025_2460272
crossref_primary_10_1186_s13019_024_02651_9
crossref_primary_10_2147_BCTT_S482504
crossref_primary_10_1002_ctm2_1480
crossref_primary_10_1097_MD_0000000000040059
crossref_primary_10_1016_j_drup_2025_101222
crossref_primary_10_3389_fonc_2023_1268584
crossref_primary_10_3390_ijms26030969
crossref_primary_10_3390_cells14020128
crossref_primary_10_1002_adma_202409378
crossref_primary_10_1016_j_fitote_2025_106480
crossref_primary_10_1016_j_inoche_2024_113098
crossref_primary_10_3390_futurepharmacol3040043
crossref_primary_10_1038_s41598_024_66401_6
crossref_primary_10_3390_ph17010100
crossref_primary_10_3390_nano14131133
crossref_primary_10_3389_fendo_2023_1260491
crossref_primary_10_1038_s41598_024_82088_1
crossref_primary_10_58803_jlar_v2i5_31
crossref_primary_10_1016_j_colsurfa_2024_133320
crossref_primary_10_3390_ijms252313165
crossref_primary_10_2174_0118715206330232240913100744
crossref_primary_10_4240_wjgs_v16_i12_3881
crossref_primary_10_1007_s12282_024_01567_5
crossref_primary_10_1016_j_jddst_2024_106331
crossref_primary_10_1515_oncologie_2024_0106
crossref_primary_10_1002_advs_202400160
crossref_primary_10_1039_D3MA00621B
crossref_primary_10_1177_10781552241279019
crossref_primary_10_1080_14737140_2024_2341737
crossref_primary_10_1080_14796694_2025_2461443
crossref_primary_10_3389_fphar_2024_1391562
crossref_primary_10_1002_jbt_70081
crossref_primary_10_1038_s41598_025_85531_z
crossref_primary_10_20517_2394_4722_2023_124
crossref_primary_10_1038_s41598_024_71076_0
crossref_primary_10_3390_genes15111458
crossref_primary_10_3389_fimmu_2024_1324959
crossref_primary_10_1016_j_intimp_2024_113447
crossref_primary_10_1186_s12957_025_03667_8
crossref_primary_10_37349_etat_2024_00215
crossref_primary_10_1016_j_electacta_2024_144205
crossref_primary_10_1016_j_actbio_2025_02_059
crossref_primary_10_1039_D3TB01957H
crossref_primary_10_3892_ol_2025_14931
crossref_primary_10_1021_acs_jmedchem_4c01458
crossref_primary_10_3389_fphar_2023_1265136
crossref_primary_10_1038_s42003_024_06548_0
crossref_primary_10_1016_j_jare_2024_08_023
crossref_primary_10_1016_j_heliyon_2024_e31586
crossref_primary_10_1038_s41598_024_65129_7
crossref_primary_10_3390_ijms25105489
crossref_primary_10_1186_s13058_024_01934_2
crossref_primary_10_1016_j_ijpharm_2025_125343
crossref_primary_10_1080_17568919_2024_2408213
crossref_primary_10_3390_healthcare12040462
crossref_primary_10_2174_0115748936293238240313081211
crossref_primary_10_1002_ame2_12434
crossref_primary_10_1002_adhm_202403715
crossref_primary_10_1007_s42247_024_00670_9
crossref_primary_10_1021_cbmi_3c00084
crossref_primary_10_1002_ctm2_1784
crossref_primary_10_1021_acs_nanolett_4c02945
crossref_primary_10_7759_cureus_47847
crossref_primary_10_1016_j_humgen_2024_201272
crossref_primary_10_1016_j_ijbiomac_2024_136661
crossref_primary_10_1021_acsami_4c17804
crossref_primary_10_1038_s41419_023_06115_1
crossref_primary_10_1016_j_mtbio_2024_101282
crossref_primary_10_1016_j_cej_2025_160811
crossref_primary_10_1016_j_jsbmb_2025_106693
crossref_primary_10_2174_0115733947278339231121105838
crossref_primary_10_3390_ijms25189991
crossref_primary_10_1016_j_gimo_2024_101961
crossref_primary_10_1080_15384047_2025_2475604
crossref_primary_10_1080_01932691_2024_2327428
crossref_primary_10_12677_jcpm_2025_41064
crossref_primary_10_1016_j_bioorg_2025_108296
crossref_primary_10_1002_iub_2933
crossref_primary_10_1016_j_genrep_2024_102038
crossref_primary_10_1016_j_jff_2024_106573
crossref_primary_10_1007_s10528_025_11034_1
crossref_primary_10_1016_j_canlet_2024_217417
crossref_primary_10_3389_fimmu_2024_1476365
crossref_primary_10_1016_j_ijbiomac_2024_131075
crossref_primary_10_3390_ijms25094647
crossref_primary_10_2174_0118715206284107231120063630
crossref_primary_10_1002_ijc_35386
crossref_primary_10_1002_cac2_12509
crossref_primary_10_1038_s41598_024_66531_x
crossref_primary_10_34133_research_0553
crossref_primary_10_1051_bioconf_202515301006
crossref_primary_10_1002_ardp_202400402
crossref_primary_10_1007_s12609_024_00549_y
crossref_primary_10_1016_j_apmt_2024_102570
crossref_primary_10_1016_j_ctrv_2024_102831
crossref_primary_10_1021_acsabm_3c01087
crossref_primary_10_1186_s12920_024_02032_0
crossref_primary_10_1002_mco2_70023
crossref_primary_10_7759_cureus_71441
crossref_primary_10_1002_ctm2_1763
crossref_primary_10_3389_fimmu_2025_1554256
crossref_primary_10_3389_fimmu_2024_1369892
crossref_primary_10_1186_s12880_024_01488_x
crossref_primary_10_1007_s11427_023_2499_2
crossref_primary_10_3390_ijms26062605
crossref_primary_10_3390_cells13100822
crossref_primary_10_3390_cimb46050282
crossref_primary_10_1016_j_cellsig_2023_111019
crossref_primary_10_1016_j_bcp_2023_115908
crossref_primary_10_3390_ijms25094620
crossref_primary_10_3390_ph16121724
crossref_primary_10_1007_s13346_024_01638_2
crossref_primary_10_1038_s41420_023_01771_w
crossref_primary_10_3389_fimmu_2024_1470167
crossref_primary_10_1136_jitc_2024_009877
crossref_primary_10_3390_cimb46110725
crossref_primary_10_1097_CM9_0000000000003007
crossref_primary_10_1016_j_cpt_2025_02_006
crossref_primary_10_7759_cureus_65230
crossref_primary_10_12677_IS_2024_61001
crossref_primary_10_20517_cdr_2024_77
crossref_primary_10_3389_fimmu_2024_1331841
crossref_primary_10_1039_D4RA03832K
crossref_primary_10_1186_s12957_024_03506_2
crossref_primary_10_1002_iid3_1284
crossref_primary_10_1016_j_gene_2025_149258
crossref_primary_10_1016_j_sajb_2025_03_001
crossref_primary_10_1016_j_jss_2024_07_071
crossref_primary_10_3389_fphar_2024_1499269
Cites_doi 10.1200/jco.2015.33.15_suppl.1082
10.1158/1078-0432.CCR-21-2600
10.1093/annonc/mdz177
10.1001/jamaoncol.2018.4224
10.1093/annonc/mdy517
10.1200/JCO.2015.64.8931
10.1007/s10549-016-3751-x
10.1016/S0140-6736(16)32454-0
10.1016/j.ejca.2021.02.028
10.1158/2159-8290.CD-16-1250
10.1016/j.semcancer.2019.12.018
10.18632/oncotarget.28083
10.3389/fimmu.2014.00308
10.1007/s10456-014-9420-y
10.1172/JCI80012
10.1007/s10549-021-06450-x
10.1158/1078-0432.CCR-15-2365
10.3390/ijms22010173
10.1093/annonc/mdu211
10.3390/cancers12123729
10.1358/dot.2016.52.1.2440714
10.1200/JCO.2012.44.7912
10.1158/1078-0432.CCR-19-2580
10.18632/oncotarget.16577
10.1002/cncr.24756
10.3390/cancers13184685
10.1038/s41523-021-00219-7
10.1200/JCO.2007.15.7842
10.1158/1078-0432.CCR-11-0509
10.1007/s11523-021-00796-4
10.3390/cancers14163860
10.1517/14712598.2012.725719
10.1056/NEJMoa1109653
10.1016/S1470-2045(20)30324-7
10.1007/s10549-020-05638-x
10.1002/cncr.32599
10.2147/CMAR.S310649
10.1016/j.semcancer.2019.07.009
10.1200/JCO.2009.23.3494
10.1186/s40364-022-00371-7
10.1016/j.annonc.2021.05.801
10.21873/anticanres.14486
10.1186/1479-5876-8-71
10.1093/annonc/mdr304
10.1158/1078-0432.CCR-21-0310
10.2147/OTT.S149245
10.1016/S1470-2045(18)30786-1
10.1007/s40265-020-01340-w
10.1158/1078-0432.CCR-10-0505
10.4110/in.2020.20.e9
10.1038/s41591-019-0432-4
10.1007/s10549-012-2110-9
10.3389/fbioe.2021.680315
10.1158/1078-0432.CCR-21-2182
10.1200/JCO.2017.75.6155
10.1200/JCO.2011.36.7771
10.18632/aging.202289
10.3892/ijo.2018.4597
10.1007/s10456-009-9160-6
10.1186/s13058-021-01463-2
10.7812/TPP/14-241
10.3389/fendo.2022.949396
10.3389/fonc.2020.582863
10.3892/ijo.2015.3306
10.3389/fonc.2021.627549
10.1158/1538-7445.SABCS15-OT1-03-05
10.1093/annonc/mdz158
10.1038/s41523-021-00240-w
10.2217/fon-2019-0762
10.2174/1570163812666150602144310
10.1007/s10549-021-06313-5
10.1016/j.jncc.2021.01.001
10.1016/s0093-7754(01)90279-9
10.1158/1078-0432.CCR-16-0190
10.1186/1479-5876-11-62
10.1155/2020/9258396
10.3332/ecancer.2019.961
10.3390/cells10113242
10.1186/s12885-015-1121-4
10.4132/jptm.2019.11.03
10.1007/s10637-010-9538-8
10.1016/j.ejca.2021.09.028
10.29252/ibj.25.3.140
10.1158/1078-0432.CCR-14-0059
10.3389/fphar.2022.838133
10.1186/1479-5876-5-42
10.3109/14653249.2010.515582
10.3390/cancers11091242
10.2217/fon-2016-0002
10.1158/1078-0432.CCR-17-2369
10.1007/s00280-015-2810-z
10.1001/jamaoncol.2015.2736
10.1016/j.fct.2022.113205
10.1634/theoncologist.2010-0081
10.7759/cureus.22575
10.1177/1060028018817904
10.3390/cancers14246034
10.1038/s41523-023-00508-3
10.3389/fendo.2019.00245
10.1200/JCO.2018.78.9909
10.1158/1078-0432.CCR-16-1423
10.1016/j.clbc.2017.05.006
10.1007/s10549-017-4537-5
10.1038/s41416-023-02158-5
10.1186/bcr3577
10.1007/s10637-013-9991-2
10.1002/mco2.103
10.1158/1078-0432.CCR-14-2258
10.4137/BCBCR.S29420
10.1016/j.annonc.2021.05.355
10.1158/1535-7163.MCT-20-0385
10.3389/fimmu.2022.795164
10.4161/23723556.2014.995033
10.1016/j.ejca.2018.11.014
10.1200/JCO.2017.73.7585
10.3390/cells9030533
10.1016/j.annonc.2020.10.471
10.1038/s41571-018-0115-y
10.1200/JCO.2004.09.005
10.7150/jca.44313
10.3109/02656736.2014.968640
10.1186/s13058-017-0807-8
10.1634/theoncologist.2019-0493
10.4155/fmc.15.93
10.1056/NEJMoa2105215
10.3389/fimmu.2022.828386
10.1158/2159-8290.CD-16-0512
10.1016/j.ejmech.2019.05.023
10.1038/s41523-022-00411-3
10.1098/rsob.210373
10.18632/oncotarget.16040
10.1186/s13058-019-1154-8
10.1016/S1470-2045(20)30754-3
10.1159/000464353
10.1093/annonc/mdz086
10.1186/1479-5876-8-53
10.2147/OTT.S65802
10.2174/1389200221666201019143252
10.3892/ol.2020.11762
10.1016/S1470-2045(14)71159-3
10.18632/oncotarget.24867
10.1016/j.breast.2022.08.010
10.1056/NEJMoa072113
10.1016/j.pharmthera.2017.12.012
10.1186/s12943-022-01712-8
10.1038/s41392-021-00828-5
10.2217/fon-2022-0812
10.3389/fimmu.2022.1018786
10.1038/s41591-018-0040-8
10.1016/S1470-2045(18)30292-4
10.1200/JCO.2008.16.1612
10.1093/annonc/mdy257
10.1007/s00018-021-03860-4
10.1007/s40265-018-1026-z
10.1200/JCO.19.00368
10.1016/S1470-2045(17)30450-3
10.1158/1078-0432.CCR-22-0305
10.3389/fphar.2018.00245
10.1158/1078-0432.CCR-17-0754
10.3390/molecules27123798
10.1158/1078-0432.CCR-19-3953
10.1200/JCO.2014.57.1513
10.1038/bjc.2016.133
10.2217/fon-2015-0054
10.1200/JCO.2010.31.2975
10.1200/JCO.19.01027
10.1016/j.cpet.2018.02.006
10.3389/fonc.2020.605633
10.1038/s41523-021-00287-9
10.1038/bjc.2017.36
10.1158/1078-0432.CCR-20-4726
10.1016/S1470-2045(19)30026-9
10.1002/cncr.23772
10.1016/j.cellsig.2022.110492
10.3389/fonc.2020.01206
10.1016/S1470-2045(20)30642-2
10.3389/fonc.2020.00584
10.1200/JCO.2005.03.047
10.1007/s40265-022-01827-8
10.1056/NEJMoa1809615
10.1158/2159-8290.CD-16-0095
10.1200/jco.2015.33.15_suppl.2508
10.1158/0008-5472.CAN-07-2765
10.1056/NEJMoa1609709
10.3390/cancers14030591
10.3389/fonc.2022.891824
10.1038/nbt.4090
10.3390/vaccines9121392
10.1200/JCO.2021.39.15_suppl.542
10.3390/vaccines10081370
10.3390/cancers12103029
10.1158/1078-0432.CCR-17-2260
10.1136/jitc-2020-SITC2020.0320
10.1158/1078-0432.CCR-18-2867
10.1007/s10637-014-0120-7
10.1200/P0.19.00221
10.1016/j.clbc.2015.07.005
10.1016/j.annonc.2020.08.2098
10.1074/jbc.M112.368282
10.2147/BCTT.S175360
10.3389/fimmu.2018.02140
10.1158/1078-0432.CCR-18-1891
10.3322/caac.21754
10.1186/s13058-020-01296-5
10.18632/oncotarget.26893
10.1158/2326-6066.CIR-14-0058
10.3389/fphar.2021.662232
10.1016/j.jconrel.2021.07.014
10.1158/2326-6066.CIR-17-0189
10.1016/j.ejphar.2016.08.022
10.1634/theoncologist.2010-0307
10.1158/1538-7445.SABCS22-GS5-03
10.1038/s41568-022-00535-5
10.1186/1756-9966-30-54
10.1016/S0140-6736(20)32531-9
10.1001/jamaoncol.2020.3524
10.1056/NEJMoa1706450
10.1200/JCO.2022.40.16_suppl.602
10.1007/s11684-021-0901-2
10.1093/annonc/mdt276
10.1093/annonc/mdz381
10.1158/2326-6066.CIR-13-0127
10.1186/s12935-021-02187-1
10.1158/1078-0432.CCR-19-3053
10.3390/cells11162508
10.1016/S1470-2045(19)30817-4
10.1093/jjco/hyt201
10.1016/j.ccell.2021.05.009
10.1016/S1470-2045(22)00694-5
10.1200/JCO.2005.05.098
10.7150/jca.7028
10.2147/IJWH.S178349
10.1007/s10549-005-7726-6
10.1007/s10637-009-9310-0
10.5306/wjco.v8.i2.120
ContentType Journal Article
Copyright 2023. The Author(s).
COPYRIGHT 2023 BioMed Central Ltd.
2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
The Author(s) 2023
Copyright_xml – notice: 2023. The Author(s).
– notice: COPYRIGHT 2023 BioMed Central Ltd.
– notice: 2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: The Author(s) 2023
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7TO
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
H94
K9.
M0S
M1P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1186/s12943-023-01805-y
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Oncogenes and Growth Factors Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One
ProQuest Central Korea
Proquest Health Research Premium Collection
Health Research Premium Collection (Alumni)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Health & Medical Collection (Alumni)
Medical Database
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
Oncogenes and Growth Factors Abstracts
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central China
ProQuest Central
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
AIDS and Cancer Research Abstracts
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList Publicly Available Content Database

CrossRef

MEDLINE - Academic


MEDLINE
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ (Directory of Open Access Journals)
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Biology
EISSN 1476-4598
EndPage 40
ExternalDocumentID oai_doaj_org_article_13ff5512c0ed47d4b8c8ba4035e35957
PMC10324146
A756212076
37415164
10_1186_s12943_023_01805_y
Genre Research Support, Non-U.S. Gov't
Journal Article
Review
GrantInformation_xml – fundername: ;
  grantid: 82203130
GroupedDBID ---
0R~
123
29M
2WC
53G
5VS
7X7
88E
8FI
8FJ
AAFWJ
AAJSJ
AASML
AAYXX
ABDBF
ABUWG
ACGFO
ACGFS
ACIHN
ACIWK
ACMJI
ACPRK
ACUHS
ADBBV
ADRAZ
ADUKV
AEAQA
AENEX
AFKRA
AFPKN
AFRAH
AHBYD
AHMBA
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C6C
CCPQU
CITATION
CS3
DIK
DU5
E3Z
EAD
EAP
EAS
EBD
EBLON
EBS
EMB
EMK
EMOBN
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
HH5
HMCUK
HYE
IAO
IHR
INH
INR
ITC
KQ8
LGEZI
LOTEE
M1P
M48
M~E
NADUK
NXXTH
O5R
O5S
OK1
OVT
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
PZZ
RBZ
RNS
ROL
RPM
RSV
SBL
SOJ
SV3
TR2
TUS
UKHRP
W2D
WOQ
WOW
XSB
-A0
3V.
ACRMQ
ADINQ
C24
CGR
CUY
CVF
ECM
EIF
FRP
NPM
PMFND
7TO
7XB
8FK
AZQEC
DWQXO
H94
K9.
PJZUB
PKEHL
PPXIY
PQEST
PQUKI
PRINS
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c564t-d4c5f9e42dcda89e7d938340b9721c9d5a47a0291b0a3c3829f94f8607ea58a83
IEDL.DBID M48
ISSN 1476-4598
IngestDate Wed Aug 27 01:21:54 EDT 2025
Thu Aug 21 18:37:07 EDT 2025
Fri Jul 11 01:14:40 EDT 2025
Fri Jul 25 21:12:33 EDT 2025
Tue Jun 17 21:33:54 EDT 2025
Tue Jun 10 20:31:29 EDT 2025
Thu Jan 02 22:43:56 EST 2025
Thu Apr 24 23:10:06 EDT 2025
Tue Jul 01 01:01:21 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Targeted therapies
Clinical trials
Breast cancer
Immune-checkpoint Inhibitors
Immunotherapy
Language English
License 2023. The Author(s).
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c564t-d4c5f9e42dcda89e7d938340b9721c9d5a47a0291b0a3c3829f94f8607ea58a83
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.1186/s12943-023-01805-y
PMID 37415164
PQID 2838786776
PQPubID 42702
PageCount 40
ParticipantIDs doaj_primary_oai_doaj_org_article_13ff5512c0ed47d4b8c8ba4035e35957
pubmedcentral_primary_oai_pubmedcentral_nih_gov_10324146
proquest_miscellaneous_2835272843
proquest_journals_2838786776
gale_infotracmisc_A756212076
gale_infotracacademiconefile_A756212076
pubmed_primary_37415164
crossref_primary_10_1186_s12943_023_01805_y
crossref_citationtrail_10_1186_s12943_023_01805_y
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2023-07-06
PublicationDateYYYYMMDD 2023-07-06
PublicationDate_xml – month: 07
  year: 2023
  text: 2023-07-06
  day: 06
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle Molecular cancer
PublicationTitleAlternate Mol Cancer
PublicationYear 2023
Publisher BioMed Central Ltd
BioMed Central
BMC
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
– name: BMC
References EP Winer (1805_CR166) 2021; 22
MA Morse (1805_CR213) 2007; 5
M Shah (1805_CR69) 2018; 32
P Safarzadeh Kozani (1805_CR238) 2022; 16
1805_CR62
L Boyero (1805_CR11) 2020; 12
SM Tolaney (1805_CR170) 2020; 6
SM Tolaney (1805_CR168) 2021; 27
L Pusztai (1805_CR183) 2021; 39
AS Alzahrani (1805_CR87) 2019; 59
J Tchou (1805_CR235) 2017; 5
1805_CR3
MG Carmichael (1805_CR204) 2010; 116
GN Hortobagyi (1805_CR78) 2016; 375
J Baselga (1805_CR140) 2012; 366
FJ Groelly (1805_CR43) 2023; 23
K Rascon (1805_CR77) 2019; 53
Y Zhang (1805_CR221) 2012; 287
H Norell (1805_CR210) 2010; 8
V Tiriveedhi (1805_CR219) 2014; 20
1805_CR66
T Kimura (1805_CR216) 2013; 13
Y Drew (1805_CR59) 2016; 114
NS Vasudev (1805_CR114) 2014; 17
RH Jones (1805_CR101) 2020; 21
Z You (1805_CR203) 2021; 21
KJ Gotink (1805_CR124) 2010; 13
JR Mackey (1805_CR123) 2015; 33
S Ahn (1805_CR112) 2020; 54
E Bornstein (1805_CR44) 2016; 52
LA Emens (1805_CR180) 2021; 32
1805_CR189
M Luque (1805_CR7) 2022; 14
E Buchbinder (1805_CR185) 2015; 125
MP Goetz (1805_CR85) 2017; 35
P Neven (1805_CR86) 2021; 23
1805_CR32
1805_CR31
NC Turner (1805_CR54) 2019; 25
S Ghosh (1805_CR14) 2021; 337
BP Schneider (1805_CR117) 2008; 26
1805_CR36
SB Kim (1805_CR107) 2017; 18
J Ettl (1805_CR57) 2018; 29
AY Ho (1805_CR171) 2020; 126
LA Emens (1805_CR178) 2019; 5
J McCain (1805_CR70) 2015; 40
EP Juliá (1805_CR176) 2018; 9
MS Dai (1805_CR147) 2021; 189
L Voorwerk (1805_CR173) 2019; 25
M Arnold (1805_CR4) 2022; 66
D Miles (1805_CR181) 2021; 32
KT Flaherty (1805_CR72) 2012; 8
HS Rugo (1805_CR127) 2011; 29
1805_CR51
A Musolino (1805_CR136) 2017; 19
NM Ayoub (1805_CR6) 2019; 11
1805_CR42
1805_CR197
M Katoh (1805_CR135) 2019; 16
1805_CR47
1805_CR193
P Schmid (1805_CR102) 2020; 38
L Lang (1805_CR105) 2020; 9
S Wedam (1805_CR142) 2020; 26
M Kalra (1805_CR63) 2021; 7
1805_CR190
MN Dickler (1805_CR83) 2017; 23
EA Mittendorf (1805_CR161) 2014; 2
GM Nitulescu (1805_CR91) 2016; 48
CR Heery (1805_CR218) 2015; 1
F Nasiri (1805_CR234) 2022; 13
1805_CR163
1805_CR97
RS Finn (1805_CR74) 2015; 16
J Baselga (1805_CR130) 2017; 17
SA Hurvitz (1805_CR55) 2020; 25
DW Miles (1805_CR121) 2013; 24
1805_CR160
KD Miller (1805_CR115) 2005; 23
K Boér (1805_CR125) 2012; 30
R Kavarthapu (1805_CR21) 2021; 13
MA Ortega (1805_CR17) 2020; 2020
V Masoud (1805_CR152) 2017; 8
CJ LaFargue (1805_CR45) 2019; 20
C Hudis (1805_CR93) 2013; 15
KB Wisinski (1805_CR94) 2016; 22
Y Assadipour (1805_CR230) 2017; 23
LM Gelbert (1805_CR80) 2014; 32
SM Domchek (1805_CR222) 2007; 67
J Cortes (1805_CR167) 2020; 396
AA Shah (1805_CR110) 2021; 22
NC Turner (1805_CR103) 2019; 30
LS Schwartzberg (1805_CR129) 2013; 19
NC Turner (1805_CR67) 2021; 27
SM Domchek (1805_CR49) 2020; 21
G Chen (1805_CR214) 2014; 2
S Loibl (1805_CR182) 2019; 30
ML Disis (1805_CR208) 2004; 22
MGC Navarrete-Bernal (1805_CR191) 2020; 10
1805_CR145
JFR Robertson (1805_CR104) 2020; 26
P Safarzadeh Kozani (1805_CR232) 2022; 10
SA Limentani (1805_CR209) 2016; 156
SK Taylor (1805_CR128) 2010; 15
D Miles (1805_CR225) 2011; 16
M Wang (1805_CR64) 2021; 2
DM Hyman (1805_CR137) 2019
EA Mittendorf (1805_CR202) 2019; 25
RH Wilson (1805_CR61) 2017; 116
J Baselga (1805_CR131) 2012; 30
N Tung (1805_CR39) 2022; 8
1805_CR92
LY Dirix (1805_CR177) 2018; 167
1805_CR96
1805_CR158
N Zacharakis (1805_CR231) 2018; 24
1805_CR155
1805_CR150
Y Liu (1805_CR217) 2020; 20
E Fakhrejahani (1805_CR132) 2014; 44
SY Bae (1805_CR5) 2015; 15
LA Emens (1805_CR215) 2009; 27
HK Patel (1805_CR38) 2018; 186
L Cortesi (1805_CR65) 2021; 16
RH Vonderheide (1805_CR188) 2010; 16
S Dees (1805_CR233) 2020; 19
TA Baudino (1805_CR30) 2015; 12
C Pucci (1805_CR149) 2019; 13
1805_CR122
DM Hyams (1805_CR126) 2013; 31
SM Hoy (1805_CR52) 2018; 78
MF Santolla (1805_CR19) 2020; 12
NK Ibrahim (1805_CR226) 2013; 4
S Toraya-Brown (1805_CR157) 2014; 30
M Oliveira (1805_CR108) 2019; 30
MA Geller (1805_CR240) 2011; 13
SJ Keam (1805_CR187) 2023; 83
A Goldhirsch (1805_CR41) 2011; 22
K Miller (1805_CR116) 2007; 357
1805_CR138
1805_CR139
K Yonemori (1805_CR48) 2021; 109
C Denkert (1805_CR154) 2017; 389
1805_CR134
A Howell (1805_CR37) 2023; 128
CM Diaz (1805_CR211) 2013; 11
M Robson (1805_CR46) 2017; 377
M Farooq (1805_CR133) 2021; 10
CO Madu (1805_CR111) 2020; 11
R Kumar (1805_CR113) 2001; 28
S Adams (1805_CR174) 2022; 28
M Cristofanilli (1805_CR76) 2022; 28
A Patsouris (1805_CR60) 2021; 159
AN Giaquinto (1805_CR2) 2022; 72
AG Mukherjee (1805_CR12) 2022; 10
MI Nounou (1805_CR148) 2015; 9
A DeMichele (1805_CR73) 2015; 21
Y He (1805_CR26) 2021; 6
C Saura (1805_CR99) 2017; 7
T Saha (1805_CR35) 2019; 177
MF Mercogliano (1805_CR9) 2020; 10
1805_CR228
S Chaudhuri (1805_CR195) 2021; 1
1805_CR224
GM Nitulescu (1805_CR89) 2018; 53
HL McArthur (1805_CR192) 2016; 22
F Cuppone (1805_CR119) 2011; 30
TA Brown 2nd (1805_CR207) 2020; 181
U Banerji (1805_CR98) 2018; 24
JB Lee (1805_CR120) 2011; 29
R Barroso-Sousa (1805_CR175) 2021
P Schmid (1805_CR179) 2018; 379
C Brignone (1805_CR194) 2010; 8
1805_CR237
1805_CR239
EA Mittendorf (1805_CR201) 2014; 25
D Presti (1805_CR18) 2019; 11
LM Smyth (1805_CR100) 2020; 26
JM Pérez-García (1805_CR169) 2021; 148
JM Martin (1805_CR81) 2018; 11
S Adams (1805_CR165) 2019; 30
GW Sledge Jr (1805_CR84) 2017; 35
Y Xing (1805_CR95) 2019; 21
JP Holmes (1805_CR200) 2008; 113
A Carvajal (1805_CR27) 2005; 94
N Turner (1805_CR109) 2022; 191
J de Bono (1805_CR53) 2017; 7
L Buckingham (1805_CR106) 2022; 12
A Lee (1805_CR146) 2020; 80
K Nurgali (1805_CR151) 2018; 9
J Foldi (1805_CR184) 2021; 7
BI Bodai (1805_CR1) 2015; 19
1805_CR205
V Tiriveedhi (1805_CR220) 2013; 138
MR Migden (1805_CR162) 2020; 16
D Tripathy (1805_CR79) 2018; 19
N Bhattacharjee (1805_CR90) 2016; 791
1805_CR15
K Garber (1805_CR236) 2018; 36
J Wesolowski (1805_CR172) 2022; 14
GT Clifton (1805_CR198) 2016; 12
PL Smith (1805_CR196) 2021; 9
HS Rugo (1805_CR227) 2022
SRD Johnston (1805_CR141) 2023; 24
H Čelešnik (1805_CR8) 2022; 14
1805_CR212
1805_CR20
1805_CR22
1805_CR25
JP Holmes (1805_CR206) 2008; 26
1805_CR24
JK Litton (1805_CR56) 2020; 31
1805_CR28
D Miricescu (1805_CR88) 2020; 22
CN Baxevanis (1805_CR153) 2021; 72
A Rani (1805_CR34) 2019; 10
L Gianni (1805_CR118) 2013; 31
T Kieber-Emmons (1805_CR223) 2014; 5
FJ Esteva (1805_CR156) 2019; 20
EL Mayer (1805_CR71) 2021; 22
AN Tutt (1805_CR50) 2021; 384
N Vidula (1805_CR75) 2016; 16
R Nanda (1805_CR164) 2016; 34
Y Hu (1805_CR68) 2021; 13
W Fan (1805_CR33) 2015; 7
M Rusidzé (1805_CR23) 2021; 78
ZB Jenner (1805_CR58) 2016; 12
B Comin-Anduix (1805_CR186) 2016; 9
TA Moo (1805_CR29) 2018; 13
DJ Slamon (1805_CR144) 2018; 36
F Schütz (1805_CR159) 2017; 40
Z Huang (1805_CR229) 2023; 22
A Patnaik (1805_CR82) 2016; 6
MM Rahman (1805_CR13) 2022; 27
GE Peoples (1805_CR199) 2005; 23
K Zhu (1805_CR40) 2022; 11
M Tufail (1805_CR16) 2022; 12
A Shah (1805_CR143) 2018; 24
J Mehanna (1805_CR10) 2019; 11
References_xml – ident: 1805_CR62
  doi: 10.1200/jco.2015.33.15_suppl.1082
– ident: 1805_CR145
  doi: 10.1158/1078-0432.CCR-21-2600
– volume: 12
  start-page: 2850
  issue: 6
  year: 2022
  ident: 1805_CR106
  publication-title: Am J Cancer Res
– volume: 30
  start-page: 1289
  issue: 8
  year: 2019
  ident: 1805_CR108
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdz177
– volume: 5
  start-page: 74
  issue: 1
  year: 2019
  ident: 1805_CR178
  publication-title: JAMA Oncol
  doi: 10.1001/jamaoncol.2018.4224
– volume: 30
  start-page: 397
  issue: 3
  year: 2019
  ident: 1805_CR165
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdy517
– volume: 34
  start-page: 2460
  issue: 21
  year: 2016
  ident: 1805_CR164
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2015.64.8931
– volume: 156
  start-page: 319
  issue: 2
  year: 2016
  ident: 1805_CR209
  publication-title: Breast Cancer Res Treat
  doi: 10.1007/s10549-016-3751-x
– volume: 389
  start-page: 2430
  issue: 10087
  year: 2017
  ident: 1805_CR154
  publication-title: Lancet
  doi: 10.1016/S0140-6736(16)32454-0
– volume: 148
  start-page: 382
  year: 2021
  ident: 1805_CR169
  publication-title: Eur J Cancer
  doi: 10.1016/j.ejca.2021.02.028
– volume: 7
  start-page: 620
  issue: 6
  year: 2017
  ident: 1805_CR53
  publication-title: Cancer Discov
  doi: 10.1158/2159-8290.CD-16-1250
– volume: 72
  start-page: 76
  year: 2021
  ident: 1805_CR153
  publication-title: Semin Cancer Biol
  doi: 10.1016/j.semcancer.2019.12.018
– ident: 1805_CR224
  doi: 10.18632/oncotarget.28083
– volume: 5
  start-page: 308
  year: 2014
  ident: 1805_CR223
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2014.00308
– volume: 17
  start-page: 471
  issue: 3
  year: 2014
  ident: 1805_CR114
  publication-title: Angiogenesis
  doi: 10.1007/s10456-014-9420-y
– volume: 125
  start-page: 3377
  issue: 9
  year: 2015
  ident: 1805_CR185
  publication-title: J Clin Investig
  doi: 10.1172/JCI80012
– volume: 191
  start-page: 565
  issue: 3
  year: 2022
  ident: 1805_CR109
  publication-title: Breast Cancer Res Treat
  doi: 10.1007/s10549-021-06450-x
– volume: 22
  start-page: 2659
  issue: 11
  year: 2016
  ident: 1805_CR94
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-15-2365
– volume: 22
  start-page: 173
  issue: 1
  year: 2020
  ident: 1805_CR88
  publication-title: Int J Mol Sci
  doi: 10.3390/ijms22010173
– volume: 25
  start-page: 1735
  issue: 9
  year: 2014
  ident: 1805_CR201
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdu211
– volume: 12
  start-page: 3729
  issue: 12
  year: 2020
  ident: 1805_CR11
  publication-title: Cancers
  doi: 10.3390/cancers12123729
– volume: 52
  start-page: 17
  issue: 1
  year: 2016
  ident: 1805_CR44
  publication-title: Drugs Today (Barc)
  doi: 10.1358/dot.2016.52.1.2440714
– volume: 31
  start-page: 1719
  issue: 14
  year: 2013
  ident: 1805_CR118
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2012.44.7912
– volume: 26
  start-page: 1208
  issue: 6
  year: 2020
  ident: 1805_CR142
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-19-2580
– ident: 1805_CR47
  doi: 10.18632/oncotarget.16577
– volume: 116
  start-page: 292
  issue: 2
  year: 2010
  ident: 1805_CR204
  publication-title: Cancer
  doi: 10.1002/cncr.24756
– volume: 13
  start-page: 4685
  issue: 18
  year: 2021
  ident: 1805_CR21
  publication-title: Cancers
  doi: 10.3390/cancers13184685
– volume: 7
  start-page: 9
  issue: 1
  year: 2021
  ident: 1805_CR184
  publication-title: NPJ Breast Cancer
  doi: 10.1038/s41523-021-00219-7
– volume: 26
  start-page: 3426
  issue: 20
  year: 2008
  ident: 1805_CR206
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2007.15.7842
– volume: 8
  start-page: 568
  issue: 2
  year: 2012
  ident: 1805_CR72
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-11-0509
– volume: 16
  start-page: 255
  issue: 3
  year: 2021
  ident: 1805_CR65
  publication-title: Target Oncol
  doi: 10.1007/s11523-021-00796-4
– volume: 14
  start-page: 3860
  issue: 16
  year: 2022
  ident: 1805_CR172
  publication-title: Cancers (Basel)
  doi: 10.3390/cancers14163860
– volume: 13
  start-page: 35
  issue: 1
  year: 2013
  ident: 1805_CR216
  publication-title: Expert Opin Biol Ther
  doi: 10.1517/14712598.2012.725719
– volume: 366
  start-page: 520
  issue: 6
  year: 2012
  ident: 1805_CR140
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1109653
– volume: 21
  start-page: 1155
  issue: 9
  year: 2020
  ident: 1805_CR49
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(20)30324-7
– volume: 181
  start-page: 391
  issue: 2
  year: 2020
  ident: 1805_CR207
  publication-title: Breast Cancer Res Treat
  doi: 10.1007/s10549-020-05638-x
– volume: 126
  start-page: 850
  issue: 4
  year: 2020
  ident: 1805_CR171
  publication-title: Cancer
  doi: 10.1002/cncr.32599
– volume: 13
  start-page: 5223
  year: 2021
  ident: 1805_CR68
  publication-title: Cancer Manag Res
  doi: 10.2147/CMAR.S310649
– volume: 59
  start-page: 125
  year: 2019
  ident: 1805_CR87
  publication-title: Semin Cancer Biol
  doi: 10.1016/j.semcancer.2019.07.009
– volume: 27
  start-page: 5911
  issue: 35
  year: 2009
  ident: 1805_CR215
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2009.23.3494
– volume: 10
  start-page: 24
  issue: 1
  year: 2022
  ident: 1805_CR232
  publication-title: Biomark Res
  doi: 10.1186/s40364-022-00371-7
– volume: 32
  start-page: 994
  issue: 8
  year: 2021
  ident: 1805_CR181
  publication-title: Ann Oncol
  doi: 10.1016/j.annonc.2021.05.801
– ident: 1805_CR31
  doi: 10.21873/anticanres.14486
– volume: 8
  start-page: 71
  year: 2010
  ident: 1805_CR194
  publication-title: J Transl Med
  doi: 10.1186/1479-5876-8-71
– volume: 22
  start-page: 1736
  issue: 8
  year: 2011
  ident: 1805_CR41
  publication-title: Ann oncol
  doi: 10.1093/annonc/mdr304
– volume: 27
  start-page: 5482
  issue: 20
  year: 2021
  ident: 1805_CR67
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-21-0310
– volume: 11
  start-page: 5253
  year: 2018
  ident: 1805_CR81
  publication-title: Onco Targets Ther
  doi: 10.2147/OTT.S149245
– volume: 20
  start-page: e15
  issue: 1
  year: 2019
  ident: 1805_CR45
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(18)30786-1
– volume: 80
  start-page: 1033
  issue: 10
  year: 2020
  ident: 1805_CR146
  publication-title: Drugs
  doi: 10.1007/s40265-020-01340-w
– volume: 16
  start-page: 3485
  issue: 13
  year: 2010
  ident: 1805_CR188
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-10-0505
– ident: 1805_CR15
  doi: 10.4110/in.2020.20.e9
– volume: 25
  start-page: 920
  issue: 6
  year: 2019
  ident: 1805_CR173
  publication-title: Nat Med
  doi: 10.1038/s41591-019-0432-4
– volume: 138
  start-page: 109
  issue: 1
  year: 2013
  ident: 1805_CR220
  publication-title: Breast Cancer Res Treat
  doi: 10.1007/s10549-012-2110-9
– ident: 1805_CR160
  doi: 10.3389/fbioe.2021.680315
– volume: 28
  start-page: 271
  issue: 2
  year: 2022
  ident: 1805_CR174
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-21-2182
– volume: 35
  start-page: 3638
  issue: 32
  year: 2017
  ident: 1805_CR85
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2017.75.6155
– volume: 30
  start-page: 1484
  issue: 13
  year: 2012
  ident: 1805_CR131
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2011.36.7771
– ident: 1805_CR24
  doi: 10.18632/aging.202289
– volume: 53
  start-page: 2319
  issue: 6
  year: 2018
  ident: 1805_CR89
  publication-title: Int J Oncol
  doi: 10.3892/ijo.2018.4597
– volume: 13
  start-page: 1
  issue: 1
  year: 2010
  ident: 1805_CR124
  publication-title: Angiogenesis
  doi: 10.1007/s10456-009-9160-6
– volume: 23
  start-page: 87
  issue: 1
  year: 2021
  ident: 1805_CR86
  publication-title: Breast Cancer Res
  doi: 10.1186/s13058-021-01463-2
– volume: 19
  start-page: 48
  issue: 2
  year: 2015
  ident: 1805_CR1
  publication-title: Perm J
  doi: 10.7812/TPP/14-241
– ident: 1805_CR25
  doi: 10.3389/fendo.2022.949396
– ident: 1805_CR36
  doi: 10.3389/fonc.2020.582863
– volume: 48
  start-page: 869
  issue: 3
  year: 2016
  ident: 1805_CR91
  publication-title: Int J Oncol
  doi: 10.3892/ijo.2015.3306
– ident: 1805_CR239
  doi: 10.3389/fonc.2021.627549
– ident: 1805_CR66
  doi: 10.1158/1538-7445.SABCS15-OT1-03-05
– volume: 30
  start-page: 1279
  issue: 8
  year: 2019
  ident: 1805_CR182
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdz158
– volume: 7
  start-page: 29
  issue: 1
  year: 2021
  ident: 1805_CR63
  publication-title: NPJ Breast Cancer
  doi: 10.1038/s41523-021-00240-w
– volume: 16
  start-page: 11
  issue: 4
  year: 2020
  ident: 1805_CR162
  publication-title: Future Oncol
  doi: 10.2217/fon-2019-0762
– volume: 12
  start-page: 3
  issue: 1
  year: 2015
  ident: 1805_CR30
  publication-title: Curr Drug Discov Technol
  doi: 10.2174/1570163812666150602144310
– volume: 189
  start-page: 665
  issue: 3
  year: 2021
  ident: 1805_CR147
  publication-title: Breast Cancer Res Treat
  doi: 10.1007/s10549-021-06313-5
– volume: 1
  start-page: 47
  issue: 2
  year: 2021
  ident: 1805_CR195
  publication-title: Journal of the National Cancer Center
  doi: 10.1016/j.jncc.2021.01.001
– volume: 28
  start-page: 27
  issue: 5 Suppl 16
  year: 2001
  ident: 1805_CR113
  publication-title: Semin Oncol
  doi: 10.1016/s0093-7754(01)90279-9
– volume: 22
  start-page: 5729
  issue: 23
  year: 2016
  ident: 1805_CR192
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-16-0190
– volume: 11
  start-page: 62
  year: 2013
  ident: 1805_CR211
  publication-title: J Transl Med
  doi: 10.1186/1479-5876-11-62
– volume: 2020
  start-page: 9258396
  year: 2020
  ident: 1805_CR17
  publication-title: J Oncol
  doi: 10.1155/2020/9258396
– volume: 13
  start-page: 961
  year: 2019
  ident: 1805_CR149
  publication-title: Ecancermedicalscience
  doi: 10.3332/ecancer.2019.961
– volume: 10
  start-page: 3242
  issue: 11
  year: 2021
  ident: 1805_CR133
  publication-title: Cells
  doi: 10.3390/cells10113242
– volume: 15
  start-page: 138
  year: 2015
  ident: 1805_CR5
  publication-title: BMC Cancer
  doi: 10.1186/s12885-015-1121-4
– volume: 54
  start-page: 34
  issue: 1
  year: 2020
  ident: 1805_CR112
  publication-title: J Pathol Transl Med
  doi: 10.4132/jptm.2019.11.03
– volume: 30
  start-page: 681
  issue: 2
  year: 2012
  ident: 1805_CR125
  publication-title: Invest New Drugs
  doi: 10.1007/s10637-010-9538-8
– volume: 159
  start-page: 283
  year: 2021
  ident: 1805_CR60
  publication-title: Eur J Cancer
  doi: 10.1016/j.ejca.2021.09.028
– ident: 1805_CR158
  doi: 10.29252/ibj.25.3.140
– volume: 20
  start-page: 5964
  issue: 23
  year: 2014
  ident: 1805_CR219
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-14-0059
– ident: 1805_CR122
  doi: 10.3389/fphar.2022.838133
– volume: 5
  start-page: 42
  year: 2007
  ident: 1805_CR213
  publication-title: J Transl Med
  doi: 10.1186/1479-5876-5-42
– volume: 13
  start-page: 98
  issue: 1
  year: 2011
  ident: 1805_CR240
  publication-title: Cytotherapy
  doi: 10.3109/14653249.2010.515582
– volume: 11
  start-page: 1242
  issue: 9
  year: 2019
  ident: 1805_CR18
  publication-title: Cancers
  doi: 10.3390/cancers11091242
– volume: 12
  start-page: 1439
  issue: 12
  year: 2016
  ident: 1805_CR58
  publication-title: Future Oncol
  doi: 10.2217/fon-2016-0002
– volume: 24
  start-page: 2999
  issue: 13
  year: 2018
  ident: 1805_CR143
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-17-2369
– ident: 1805_CR92
  doi: 10.1007/s00280-015-2810-z
– volume: 1
  start-page: 1087
  issue: 8
  year: 2015
  ident: 1805_CR218
  publication-title: JAMA Oncol
  doi: 10.1001/jamaoncol.2015.2736
– ident: 1805_CR150
  doi: 10.1016/j.fct.2022.113205
– volume: 19
  start-page: 2745
  issue: 10
  year: 2013
  ident: 1805_CR129
  publication-title: Clin Cancer Res
  doi: 10.1634/theoncologist.2010-0081
– ident: 1805_CR42
  doi: 10.7759/cureus.22575
– volume: 53
  start-page: 501
  issue: 5
  year: 2019
  ident: 1805_CR77
  publication-title: Ann Pharmacother
  doi: 10.1177/1060028018817904
– volume: 14
  start-page: 6034
  issue: 24
  year: 2022
  ident: 1805_CR7
  publication-title: Cancers
  doi: 10.3390/cancers14246034
– ident: 1805_CR155
  doi: 10.1038/s41523-023-00508-3
– volume: 10
  start-page: 245
  year: 2019
  ident: 1805_CR34
  publication-title: Front Endocrinol
  doi: 10.3389/fendo.2019.00245
– volume: 36
  start-page: 2465
  issue: 24
  year: 2018
  ident: 1805_CR144
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2018.78.9909
– volume: 23
  start-page: 4347
  issue: 15
  year: 2017
  ident: 1805_CR230
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-16-1423
– volume: 17
  start-page: 585
  issue: 8
  year: 2017
  ident: 1805_CR130
  publication-title: Clin Breast Cancer
  doi: 10.1016/j.clbc.2017.05.006
– volume: 167
  start-page: 671
  issue: 3
  year: 2018
  ident: 1805_CR177
  publication-title: Breast cancer Res Treat
  doi: 10.1007/s10549-017-4537-5
– volume: 128
  start-page: 421
  issue: 3
  year: 2023
  ident: 1805_CR37
  publication-title: Br J Cancer
  doi: 10.1038/s41416-023-02158-5
– volume: 15
  start-page: R110
  issue: 6
  year: 2013
  ident: 1805_CR93
  publication-title: Breast Cancer Res
  doi: 10.1186/bcr3577
– volume: 31
  start-page: 1345
  issue: 5
  year: 2013
  ident: 1805_CR126
  publication-title: Invest New Drugs
  doi: 10.1007/s10637-013-9991-2
– volume: 2
  start-page: 654
  issue: 4
  year: 2021
  ident: 1805_CR64
  publication-title: MedComm
  doi: 10.1002/mco2.103
– volume: 21
  start-page: 995
  issue: 5
  year: 2015
  ident: 1805_CR73
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-14-2258
– volume: 9
  start-page: 17
  issue: Suppl 2
  year: 2015
  ident: 1805_CR148
  publication-title: Breast Cancer (Auckl)
  doi: 10.4137/BCBCR.S29420
– volume: 32
  start-page: 983
  issue: 8
  year: 2021
  ident: 1805_CR180
  publication-title: Ann Oncol
  doi: 10.1016/j.annonc.2021.05.355
– volume: 19
  start-page: 2409
  issue: 12
  year: 2020
  ident: 1805_CR233
  publication-title: Mol Cancer Ther
  doi: 10.1158/1535-7163.MCT-20-0385
– ident: 1805_CR237
  doi: 10.3389/fimmu.2022.795164
– ident: 1805_CR22
  doi: 10.4161/23723556.2014.995033
– volume: 109
  start-page: 84
  year: 2021
  ident: 1805_CR48
  publication-title: Eur J Cancer
  doi: 10.1016/j.ejca.2018.11.014
– volume: 35
  start-page: 2875
  issue: 25
  year: 2017
  ident: 1805_CR84
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2017.73.7585
– volume: 9
  start-page: 533
  issue: 3
  year: 2020
  ident: 1805_CR105
  publication-title: Cells
  doi: 10.3390/cells9030533
– ident: 1805_CR51
  doi: 10.1016/j.annonc.2020.10.471
– volume: 16
  start-page: 105
  issue: 2
  year: 2019
  ident: 1805_CR135
  publication-title: Nat Rev Clin Oncol
  doi: 10.1038/s41571-018-0115-y
– volume: 22
  start-page: 1916
  issue: 10
  year: 2004
  ident: 1805_CR208
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2004.09.005
– volume: 15
  start-page: 810
  issue: 8
  year: 2010
  ident: 1805_CR128
  publication-title: Oncologist
  doi: 10.1634/theoncologist.2010-0081
– volume: 11
  start-page: 4474
  issue: 15
  year: 2020
  ident: 1805_CR111
  publication-title: J Cancer
  doi: 10.7150/jca.44313
– volume: 30
  start-page: 531
  issue: 8
  year: 2014
  ident: 1805_CR157
  publication-title: Int J Hyperthermia
  doi: 10.3109/02656736.2014.968640
– volume: 19
  start-page: 18
  issue: 1
  year: 2017
  ident: 1805_CR136
  publication-title: Breast Cancer Res
  doi: 10.1186/s13058-017-0807-8
– volume: 25
  start-page: 439
  issue: 3
  year: 2020
  ident: 1805_CR55
  publication-title: Oncologist
  doi: 10.1634/theoncologist.2019-0493
– volume: 7
  start-page: 1511
  issue: 12
  year: 2015
  ident: 1805_CR33
  publication-title: Future Med Chem
  doi: 10.4155/fmc.15.93
– volume: 384
  start-page: 2394
  issue: 25
  year: 2021
  ident: 1805_CR50
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa2105215
– ident: 1805_CR197
  doi: 10.3389/fimmu.2022.828386
– volume: 7
  start-page: 102
  issue: 1
  year: 2017
  ident: 1805_CR99
  publication-title: Cancer Discov
  doi: 10.1158/2159-8290.CD-16-0512
– volume: 177
  start-page: 116
  year: 2019
  ident: 1805_CR35
  publication-title: Eur J Med Chem
  doi: 10.1016/j.ejmech.2019.05.023
– volume: 8
  start-page: 47
  issue: 1
  year: 2022
  ident: 1805_CR39
  publication-title: NPJ Breast Cancer
  doi: 10.1038/s41523-022-00411-3
– ident: 1805_CR134
  doi: 10.1098/rsob.210373
– ident: 1805_CR28
  doi: 10.18632/oncotarget.16040
– volume: 21
  start-page: 78
  issue: 1
  year: 2019
  ident: 1805_CR95
  publication-title: Breast Cancer Res
  doi: 10.1186/s13058-019-1154-8
– volume: 22
  start-page: 499
  issue: 4
  year: 2021
  ident: 1805_CR166
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(20)30754-3
– volume: 40
  start-page: 294
  issue: 5
  year: 2017
  ident: 1805_CR159
  publication-title: Oncol Res Treat
  doi: 10.1159/000464353
– volume: 30
  start-page: 774
  issue: 5
  year: 2019
  ident: 1805_CR103
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdz086
– volume: 8
  start-page: 53
  year: 2010
  ident: 1805_CR210
  publication-title: J Transl Med
  doi: 10.1186/1479-5876-8-53
– volume: 9
  start-page: 1767
  year: 2016
  ident: 1805_CR186
  publication-title: Onco Targets Ther
  doi: 10.2147/OTT.S65802
– volume: 22
  start-page: 50
  issue: 1
  year: 2021
  ident: 1805_CR110
  publication-title: Curr Drug Metab
  doi: 10.2174/1389200221666201019143252
– volume: 20
  start-page: 2369
  issue: 3
  year: 2020
  ident: 1805_CR217
  publication-title: Oncol Lett
  doi: 10.3892/ol.2020.11762
– volume: 16
  start-page: 25
  issue: 1
  year: 2015
  ident: 1805_CR74
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(14)71159-3
– ident: 1805_CR189
  doi: 10.18632/oncotarget.24867
– volume: 66
  start-page: 15
  year: 2022
  ident: 1805_CR4
  publication-title: Breast J
  doi: 10.1016/j.breast.2022.08.010
– volume: 357
  start-page: 2666
  issue: 26
  year: 2007
  ident: 1805_CR116
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa072113
– volume: 186
  start-page: 1
  year: 2018
  ident: 1805_CR38
  publication-title: Pharmacol Ther
  doi: 10.1016/j.pharmthera.2017.12.012
– volume: 22
  start-page: 22
  issue: 1
  year: 2023
  ident: 1805_CR229
  publication-title: Mol Cancer
  doi: 10.1186/s12943-022-01712-8
– volume: 6
  start-page: 425
  issue: 1
  year: 2021
  ident: 1805_CR26
  publication-title: Signal transduct target Ther
  doi: 10.1038/s41392-021-00828-5
– year: 2022
  ident: 1805_CR227
  publication-title: Future Oncol
  doi: 10.2217/fon-2022-0812
– volume: 13
  start-page: 1018786
  year: 2022
  ident: 1805_CR234
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2022.1018786
– volume: 24
  start-page: 724
  issue: 6
  year: 2018
  ident: 1805_CR231
  publication-title: Nat Med
  doi: 10.1038/s41591-018-0040-8
– volume: 19
  start-page: 904
  issue: 7
  year: 2018
  ident: 1805_CR79
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(18)30292-4
– volume: 26
  start-page: 4672
  issue: 28
  year: 2008
  ident: 1805_CR117
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2008.16.1612
– volume: 29
  start-page: 1939
  issue: 9
  year: 2018
  ident: 1805_CR57
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdy257
– volume: 78
  start-page: 5681
  issue: 15
  year: 2021
  ident: 1805_CR23
  publication-title: Cell Mol Life Sci
  doi: 10.1007/s00018-021-03860-4
– volume: 78
  start-page: 1939
  issue: 18
  year: 2018
  ident: 1805_CR52
  publication-title: Drugs
  doi: 10.1007/s40265-018-1026-z
– volume: 38
  start-page: 423
  issue: 5
  year: 2020
  ident: 1805_CR102
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.19.00368
– volume: 18
  start-page: 1360
  issue: 10
  year: 2017
  ident: 1805_CR107
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(17)30450-3
– volume: 28
  start-page: 3433
  issue: 16
  year: 2022
  ident: 1805_CR76
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-22-0305
– volume: 9
  start-page: 245
  year: 2018
  ident: 1805_CR151
  publication-title: Front Pharmacol
  doi: 10.3389/fphar.2018.00245
– volume: 23
  start-page: 5218
  issue: 17
  year: 2017
  ident: 1805_CR83
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-17-0754
– volume: 27
  start-page: 3798
  issue: 12
  year: 2022
  ident: 1805_CR13
  publication-title: Molecules
  doi: 10.3390/molecules27123798
– volume: 32
  start-page: 216
  issue: 5
  year: 2018
  ident: 1805_CR69
  publication-title: Oncology (Williston Park)
– volume: 26
  start-page: 3947
  issue: 15
  year: 2020
  ident: 1805_CR100
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-19-3953
– volume: 33
  start-page: 141
  issue: 2
  year: 2015
  ident: 1805_CR123
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2014.57.1513
– volume: 114
  start-page: 723
  issue: 7
  year: 2016
  ident: 1805_CR59
  publication-title: Br J Cancer
  doi: 10.1038/bjc.2016.133
– volume: 12
  start-page: 1321
  issue: 11
  year: 2016
  ident: 1805_CR198
  publication-title: Future Oncol
  doi: 10.2217/fon-2015-0054
– volume: 29
  start-page: 2459
  issue: 18
  year: 2011
  ident: 1805_CR127
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2010.31.2975
– ident: 1805_CR96
  doi: 10.1200/JCO.19.01027
– volume: 13
  start-page: 339
  issue: 3
  year: 2018
  ident: 1805_CR29
  publication-title: PET Clin
  doi: 10.1016/j.cpet.2018.02.006
– ident: 1805_CR228
  doi: 10.3389/fonc.2020.605633
– year: 2021
  ident: 1805_CR175
  publication-title: NPJ Breast Cancer
  doi: 10.1038/s41523-021-00287-9
– volume: 116
  start-page: 884
  issue: 7
  year: 2017
  ident: 1805_CR61
  publication-title: Br J Cancer
  doi: 10.1038/bjc.2017.36
– volume: 27
  start-page: 3061
  issue: 11
  year: 2021
  ident: 1805_CR168
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-20-4726
– volume: 20
  start-page: 175
  issue: 3
  year: 2019
  ident: 1805_CR156
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(19)30026-9
– volume: 113
  start-page: 1666
  issue: 7
  year: 2008
  ident: 1805_CR200
  publication-title: Cancer
  doi: 10.1002/cncr.23772
– ident: 1805_CR20
  doi: 10.1016/j.cellsig.2022.110492
– volume: 10
  start-page: 1206
  year: 2020
  ident: 1805_CR191
  publication-title: Front Oncol
  doi: 10.3389/fonc.2020.01206
– volume: 22
  start-page: 212
  issue: 2
  year: 2021
  ident: 1805_CR71
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(20)30642-2
– volume: 10
  start-page: 584
  year: 2020
  ident: 1805_CR9
  publication-title: Front Oncol
  doi: 10.3389/fonc.2020.00584
– volume: 23
  start-page: 7536
  issue: 30
  year: 2005
  ident: 1805_CR199
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2005.03.047
– volume: 83
  start-page: 93
  issue: 1
  year: 2023
  ident: 1805_CR187
  publication-title: Drugs
  doi: 10.1007/s40265-022-01827-8
– volume: 379
  start-page: 2108
  issue: 22
  year: 2018
  ident: 1805_CR179
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1809615
– volume: 6
  start-page: 740
  issue: 7
  year: 2016
  ident: 1805_CR82
  publication-title: Cancer Discov
  doi: 10.1158/2159-8290.CD-16-0095
– ident: 1805_CR138
  doi: 10.1200/jco.2015.33.15_suppl.2508
– volume: 67
  start-page: 10546
  issue: 21
  year: 2007
  ident: 1805_CR222
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-07-2765
– volume: 375
  start-page: 1738
  issue: 18
  year: 2016
  ident: 1805_CR78
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1609709
– volume: 14
  start-page: 591
  issue: 3
  year: 2022
  ident: 1805_CR8
  publication-title: Cancers
  doi: 10.3390/cancers14030591
– ident: 1805_CR3
  doi: 10.3389/fonc.2022.891824
– volume: 36
  start-page: 215
  issue: 3
  year: 2018
  ident: 1805_CR236
  publication-title: Nat Biotechnol
  doi: 10.1038/nbt.4090
– volume: 9
  start-page: 1392
  issue: 12
  year: 2021
  ident: 1805_CR196
  publication-title: Vaccines (Basel)
  doi: 10.3390/vaccines9121392
– ident: 1805_CR205
  doi: 10.1200/JCO.2021.39.15_suppl.542
– volume: 10
  start-page: 1370
  issue: 8
  year: 2022
  ident: 1805_CR12
  publication-title: Vaccines
  doi: 10.3390/vaccines10081370
– volume: 12
  start-page: 3029
  issue: 10
  year: 2020
  ident: 1805_CR19
  publication-title: Cancers
  doi: 10.3390/cancers12103029
– volume: 24
  start-page: 2050
  issue: 9
  year: 2018
  ident: 1805_CR98
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-17-2260
– ident: 1805_CR212
  doi: 10.1136/jitc-2020-SITC2020.0320
– volume: 25
  start-page: 4248
  issue: 14
  year: 2019
  ident: 1805_CR202
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-18-2867
– volume: 32
  start-page: 825
  issue: 5
  year: 2014
  ident: 1805_CR80
  publication-title: Invest New Drugs
  doi: 10.1007/s10637-014-0120-7
– year: 2019
  ident: 1805_CR137
  publication-title: JCO Precis Oncol
  doi: 10.1200/P0.19.00221
– volume: 16
  start-page: 8
  issue: 1
  year: 2016
  ident: 1805_CR75
  publication-title: Clin Breast Cancer
  doi: 10.1016/j.clbc.2015.07.005
– volume: 31
  start-page: 1526
  issue: 11
  year: 2020
  ident: 1805_CR56
  publication-title: Ann Oncol
  doi: 10.1016/j.annonc.2020.08.2098
– volume: 287
  start-page: 32494
  issue: 39
  year: 2012
  ident: 1805_CR221
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M112.368282
– volume: 11
  start-page: 53
  year: 2019
  ident: 1805_CR6
  publication-title: Breast Cancer Targets Ther
  doi: 10.2147/BCTT.S175360
– volume: 9
  start-page: 2140
  year: 2018
  ident: 1805_CR176
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2018.02140
– volume: 25
  start-page: 2717
  issue: 9
  year: 2019
  ident: 1805_CR54
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-18-1891
– volume: 72
  start-page: 524
  issue: 6
  year: 2022
  ident: 1805_CR2
  publication-title: CA Cancer J Clin
  doi: 10.3322/caac.21754
– ident: 1805_CR32
  doi: 10.1186/s13058-020-01296-5
– ident: 1805_CR190
  doi: 10.18632/oncotarget.26893
– volume: 2
  start-page: 949
  issue: 10
  year: 2014
  ident: 1805_CR214
  publication-title: Cancer Immunol Res
  doi: 10.1158/2326-6066.CIR-14-0058
– ident: 1805_CR97
  doi: 10.3389/fphar.2021.662232
– volume: 337
  start-page: 27
  year: 2021
  ident: 1805_CR14
  publication-title: J Control Release
  doi: 10.1016/j.jconrel.2021.07.014
– volume: 5
  start-page: 1152
  issue: 12
  year: 2017
  ident: 1805_CR235
  publication-title: Cancer Immunol Res
  doi: 10.1158/2326-6066.CIR-17-0189
– volume: 791
  start-page: 8
  year: 2016
  ident: 1805_CR90
  publication-title: Eur J Pharmacol
  doi: 10.1016/j.ejphar.2016.08.022
– volume: 16
  start-page: 1092
  issue: 8
  year: 2011
  ident: 1805_CR225
  publication-title: Oncologist
  doi: 10.1634/theoncologist.2010-0307
– ident: 1805_CR163
  doi: 10.1158/1538-7445.SABCS22-GS5-03
– volume: 23
  start-page: 78
  issue: 2
  year: 2023
  ident: 1805_CR43
  publication-title: Nat Rev Cancer
  doi: 10.1038/s41568-022-00535-5
– volume: 30
  start-page: 54
  issue: 1
  year: 2011
  ident: 1805_CR119
  publication-title: J Exp Clin Cancer Res
  doi: 10.1186/1756-9966-30-54
– volume: 396
  start-page: 1817
  issue: 10265
  year: 2020
  ident: 1805_CR167
  publication-title: Lancet
  doi: 10.1016/S0140-6736(20)32531-9
– volume: 6
  start-page: 1598
  issue: 10
  year: 2020
  ident: 1805_CR170
  publication-title: JAMA Oncol
  doi: 10.1001/jamaoncol.2020.3524
– volume: 377
  start-page: 523
  issue: 6
  year: 2017
  ident: 1805_CR46
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1706450
– ident: 1805_CR193
  doi: 10.1200/JCO.2022.40.16_suppl.602
– volume: 16
  start-page: 322
  issue: 3
  year: 2022
  ident: 1805_CR238
  publication-title: Front Med
  doi: 10.1007/s11684-021-0901-2
– volume: 24
  start-page: 2773
  issue: 11
  year: 2013
  ident: 1805_CR121
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdt276
– ident: 1805_CR139
  doi: 10.1093/annonc/mdz381
– volume: 2
  start-page: 361
  issue: 4
  year: 2014
  ident: 1805_CR161
  publication-title: Cancer Immunol Res
  doi: 10.1158/2326-6066.CIR-13-0127
– volume: 21
  start-page: 489
  issue: 1
  year: 2021
  ident: 1805_CR203
  publication-title: Cancer Cell Int
  doi: 10.1186/s12935-021-02187-1
– volume: 26
  start-page: 1574
  issue: 7
  year: 2020
  ident: 1805_CR104
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-19-3053
– volume: 11
  start-page: 2508
  issue: 16
  year: 2022
  ident: 1805_CR40
  publication-title: Cells
  doi: 10.3390/cells11162508
– volume: 21
  start-page: 345
  issue: 3
  year: 2020
  ident: 1805_CR101
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(19)30817-4
– volume: 44
  start-page: 197
  issue: 3
  year: 2014
  ident: 1805_CR132
  publication-title: Jpn J Clin Oncol
  doi: 10.1093/jjco/hyt201
– volume: 39
  start-page: 989
  issue: 7
  year: 2021
  ident: 1805_CR183
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2021.05.009
– volume: 24
  start-page: 77
  year: 2023
  ident: 1805_CR141
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(22)00694-5
– volume: 23
  start-page: 792
  issue: 4
  year: 2005
  ident: 1805_CR115
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2005.05.098
– volume: 4
  start-page: 577
  issue: 7
  year: 2013
  ident: 1805_CR226
  publication-title: J Cancer
  doi: 10.7150/jca.7028
– volume: 11
  start-page: 431
  year: 2019
  ident: 1805_CR10
  publication-title: Int J Womens Health
  doi: 10.2147/IJWH.S178349
– volume: 94
  start-page: 171
  issue: 2
  year: 2005
  ident: 1805_CR27
  publication-title: Breast Cancer Res Treat
  doi: 10.1007/s10549-005-7726-6
– volume: 12
  start-page: 2920
  issue: 7
  year: 2022
  ident: 1805_CR16
  publication-title: Am J Cancer Res
– volume: 40
  start-page: 511
  issue: 8
  year: 2015
  ident: 1805_CR70
  publication-title: P T
– volume: 29
  start-page: 182
  issue: 1
  year: 2011
  ident: 1805_CR120
  publication-title: Invest New Drugs
  doi: 10.1007/s10637-009-9310-0
– volume: 8
  start-page: 120
  issue: 2
  year: 2017
  ident: 1805_CR152
  publication-title: World J Clin Oncol
  doi: 10.5306/wjco.v8.i2.120
SSID ssj0017874
Score 2.713469
SecondaryResourceType review_article
Snippet Breast cancer is the second leading cause of death for women worldwide. The heterogeneity of this disease presents a big challenge in its therapeutic...
Abstract Breast cancer is the second leading cause of death for women worldwide. The heterogeneity of this disease presents a big challenge in its therapeutic...
SourceID doaj
pubmedcentral
proquest
gale
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 105
SubjectTerms Angiogenesis
Breast cancer
Cancer
Cancer therapies
Cell cycle
Chemotherapy
Clinical aspects
Clinical trials
Combined Modality Therapy
Cyclin-dependent kinases
Development and progression
Disease management
DNA repair
Drug approval
Drug development
Drug therapy
Enzymes
Epidermal growth factor
Estrogens
Fatalities
FDA approval
Female
Fibroblasts
Growth factors
Health aspects
Humans
Immune checkpoint inhibitors
Immunosuppressive agents
Immunotherapy
Immunotherapy - methods
Ipilimumab
Kinases
Medical prognosis
Metastasis
Molecular biology
Molecular Targeted Therapy - methods
Monosaccharides
Patients
Phosphorylation
Proteins
Radiation therapy
Review
Sugars
Targeted therapies
Therapeutic targets
Triple Negative Breast Neoplasms - drug therapy
Triple Negative Breast Neoplasms - pathology
Vaccination
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Na9wwEBUlkNJLadIvt2lQoNBDMZEt2ZaO29IQAsmpobkJaSTTheIN2c1h_31nJHtZU2gvvXokI2lmPCNr3hNjH3shvY5VVaIBQ6kMxFJD25QOalAAPQYN-g95fdNe3qqru-Zu76ovqgnL9MB54c4r2fcY1WsQMaguKK9Be6eEbCJhShOOHGPetJkazw_QDNUEkdHt-RqjmqLzSqod0qIpt7MwlNj6__wm7wWlecHkXgS6eMGej6kjX-QhH7EncThmh_kyye0xe3o9HpO_ZD8W-WQ_wdf4cuAT_pG7hKxc81XPcw14DDxDsLbcDYEvCS6ymp5gT09F6xsO9LqHV-z24tv3r5fleINCCU2rNmVQ0PQmqjpAcNrELhjckSrhibMHTGic6pyoTeWFkyB1bXqjet2KLrpGOy1fs4NhNcS3jANgcoEi7IJZoInGRFz21oOQta-6vmDVtKAWRnpxuuXil03bDN3arASLSrBJCXZbsM-7PveZXOOvrb-QnnYtiRg7PUBzsaO52H-ZS8E-kZYtuS8OD9yIQsBJEhGWXXSYEFa16NqCncxaotvBXDzZiR3dfm0xV9MdMQSi-Gwnpp5UyjbE1WNq09QdZgWyYG-yWe2mJCm_ww1swfTM4GZznkuG5c9ECk7EiOhX7bv_sUrv2bM6OQuVRp6wg83DY_yAydfGnyY_-w3U9Cn_
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3daxQxEA9aUXwRrV9bq0QQfJCl-5HNx5OcYilCfbJ4byE7yepB2a1314f77zuTzZ5dhL5ukiO5mcn8ksz8hrEPXVG3OpRljgoMuTAQcg2yyR1UIAA6dBp0D3n-Q55diO_LZpku3DYprHLaE-NG7QegO_ITdINaEfma_Hz1N6eqUfS6mkpo3GcPiLqMQrrUcn_gKlEZxZQoo-XJBn2boFdLiiDSRZPvZs4ocvb_vzPfck3zsMlbfuj0KXuSACRfjBJ_xu6F_pA9HEtK7g7Zo_P0WP6c_VqM7_sxiY2vej5lQXIX8ys3fOj4GAkePB8TsXbc9Z6vKGlkmL7gyJZC17cc6OfWL9jF6befX8_yVEchh0aKbe4FNJ0JovLgnTZBeYPnUlG0xNwDxjdOKFdUpmwLV0OtK9MZ0WlZqOAa7XT9kh30Qx9eMw6AEAObcAhiQROMCQg4ZAtFXbWl6jJWTn-ohUQyTrUuLm08bGhpRyFYFIKNQrC7jH3aj7kaKTbu7P2F5LTvSfTY8cOw_m2Ttdmy7jqEghUUwQvlRatBtzjlugmUiKwy9pGkbMmIcXrgUi4CLpLosOxCISwsq0LJjB3PeqLxwbx50hObjH9j_6lqxt7vm2kkBbT1YbiOfZpKITaoM_ZqVKv9kmpCeXiMzZieKdxszfOWfvUnUoMTPSJalzy6e15v2OMqmgGFPh6zg-36OrxFcLVt30ULugF49yHy
  priority: 102
  providerName: ProQuest
Title Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer
URI https://www.ncbi.nlm.nih.gov/pubmed/37415164
https://www.proquest.com/docview/2838786776
https://www.proquest.com/docview/2835272843
https://pubmed.ncbi.nlm.nih.gov/PMC10324146
https://doaj.org/article/13ff5512c0ed47d4b8c8ba4035e35957
Volume 22
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3di9NAEB_uA8UX0fMrepYVBB8kmo9NdvdBpCd3HIUeohb7tiSTjRaOVNse2P_emU1SL3jcUyGzm-5mZjK_zXwBvK6jtNQujkMSYAylQRdqzLOwwAQlYk1Gg79DTi_y85mczLP5HvTtjroHuL7xaMf9pGary3d_fm8_ksJ_8Aqv8_drslmSvZEcGaSjLNzuwyH9iWJFncp_XgUSTu9llioPZWZ0n0Rz4z0GhsrX8___rX3NbA1DKq_ZqLMHcL8Dl2LcSsND2HPNEdxp201uj-DutHOkP4Lv49b37xPcxKIRfYakKHzu5Vosa9FGibtKtElaW1E0lVhwQsmyv0IzSw5r3wjk260ew-zs9Nun87DrsRBilstNWEnMauNkUmFVaONUZejMKqOSq_qgqbJCqiJKTFxGRYqpTkxtZK3zSLki04VOn8BBs2zcMxCIBD-IRFMIJxpnjCMwkpcYpUkZqzqAuH-gFrsC5NwH49L6g4jObcsES0ywngl2G8Db3ZxfbfmNW0efMJ92I7l0tr-wXP2wnSbaOK1rgokJRq6SqpKlRl3SktPMcZKyCuANc9myyNHysOjyFGiTXCrLjhVBxjiJVB7A8WAkKSYOyb2c2F6uLaE5rbiGIJFf7cg8k4PdGre88mOyRBFuSAN42orVbkspI0A64gagBwI32POQ0ix--rLhXDqRNC9_fvuyX8C9xKsBh0Uew8FmdeVeEvDalCPYV3M1gsPxePJ1Qr8npxefv4z8Z4yR17S_zRQr0g
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB6VrXhcEJRXoICRQBxQ1MRxEueA0BZabWl3hVArenOTiQMroaTsboXyp_iNzOSxNELqrVe_ZGdmPN_E8wB4XXhBpq3vu8TA6KoErasxCt0UJSrEgpQG_4eczqLJifp8Gp5uwJ8-FobdKvs7sbmo8wr5H_kOqUEdc_K16MP5L5erRvHral9Co2WLQ1v_JpNt-f7gE9H3jZT7e8cfJ25XVcDFMFIrN1cYFolVMsc81YmN84SsNOVlnMcGkzxMVZx6MvEzLw0w0DIpElXoyIttGupUB7TuDdhUAZkyI9jc3Zt9-bp-tyD2V31ojo52lqRNFb-Tss-S9kK3Hqi_pkrA_7rgkjIcOmpe0nz79-BuB1nFuOWx-7Bhyy242RaxrLfg1rR7nn8A38atR0ETNifmpejjLkXaRHQuRVWI1vfc5qIN_apFWuZizmEqVd9CMzN2ll8J5OUWD-HkWr7xIxiVVWmfgEAkUENdNIXQZ2KTxBLEiTL0Apn5ceGA339Qg11ac66u8dM05o2OTEsEQ0QwDRFM7cC79ZzzNqnHlaN3mU7rkZyQu2moFt9NJ9_GD4qCwKdEz-YqzlWmUWe05SC0HPocO_CWqWz42qDtYdpFP9AhOQGXGccERH3pxZED24ORJO447O75xHTXzdL8Ew4HXq27eSa70JW2umjGhDImNBI48Lhlq_WRAsaVZDg7oAcMNzjzsKec_2iSkXNCRpLn6OnV-3oJtyfH0yNzdDA7fAZ3ZCMS7Hi5DaPV4sI-J2i3yl508iTg7LpF-C-pXF_P
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Advancements+in+clinical+aspects+of+targeted+therapy+and+immunotherapy+in+breast+cancer&rft.jtitle=Molecular+cancer&rft.au=Ye%2C+Feng&rft.au=Dewanjee%2C+Saikat&rft.au=Li%2C+Yuehua&rft.au=Jha%2C+Niraj+Kumar&rft.date=2023-07-06&rft.pub=BioMed+Central+Ltd&rft.issn=1476-4598&rft.eissn=1476-4598&rft.volume=22&rft.issue=1&rft_id=info:doi/10.1186%2Fs12943-023-01805-y&rft.externalDocID=A756212076
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1476-4598&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1476-4598&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1476-4598&client=summon